CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 199 filers reported holding CLOVIS ONCOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.94 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $50,634,000 | +23.2% | 1,139,890 | 0.0% | 2.01% | +9.2% |
Q3 2016 | $41,093,000 | +162.8% | 1,139,890 | 0.0% | 1.84% | +127.1% |
Q2 2016 | $15,639,000 | -28.5% | 1,139,890 | 0.0% | 0.81% | -44.1% |
Q1 2016 | $21,886,000 | -45.1% | 1,139,890 | 0.0% | 1.45% | -42.8% |
Q4 2015 | $39,896,000 | -61.9% | 1,139,890 | 0.0% | 2.54% | -63.2% |
Q3 2015 | $104,824,000 | +4.6% | 1,139,890 | 0.0% | 6.91% | +32.0% |
Q2 2015 | $100,174,000 | -40.8% | 1,139,890 | -50.0% | 5.23% | -31.6% |
Q1 2015 | $169,228,000 | +32.6% | 2,279,781 | 0.0% | 7.65% | +23.6% |
Q4 2014 | $127,668,000 | +23.5% | 2,279,781 | 0.0% | 6.19% | +17.8% |
Q3 2014 | $103,411,000 | +9.5% | 2,279,781 | 0.0% | 5.26% | +18.7% |
Q2 2014 | $94,406,000 | -40.2% | 2,279,781 | 0.0% | 4.43% | -42.9% |
Q1 2014 | $157,920,000 | +14.9% | 2,279,781 | 0.0% | 7.75% | +16.8% |
Q4 2013 | $137,402,000 | -0.9% | 2,279,781 | 0.0% | 6.64% | +20.9% |
Q3 2013 | $138,611,000 | -9.2% | 2,279,781 | 0.0% | 5.49% | -19.5% |
Q2 2013 | $152,700,000 | – | 2,279,781 | – | 6.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |